You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Novavax(NVAX.US)新冠疫苗初步數據顯示可預防Omicron
阿思達克 12-23 11:35
Novavax(NVAX.US)公佈,初步數據顯示其新冠疫苗NVX-CoV2373似乎對新冠變種病毒Omicron產生有效的免疫反應。根據其加強劑和青少年研究的早期數據,兩次注射對Omicron和其他循環變異體具有「廣泛交叉反應性」,六個月後第三次注射後有關反應增加。在試驗中,該注射劑顯示出高達90.4%的功效。 Novavax研發總監Gregory M Glenn表示,有關結果顯示疫苗可在對抗新冠變種病毒的持續鬥爭中發揮重要作用。另或須開發專門針對Omicron的疫苗作爲應對病毒的持續進化,預期將於明年1月起投產。 該股隔晚收市價跌4.07%,報183.3美元,市後交易時段暫升5%,報192.5美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account